Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Achilles Therapeutics plc (ACHL) will be presenting at the 10th Annual Immuno-Oncology 360 Conference to discuss precision T cell therapies targeting clonal neoantigens for solid tumors. The presentation will be led by Sergio Quezada, PhD, the Chief Scientific Officer, and will take place in New York on February 29, 2024.
02/05/2024 - 07:00 AM
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:
10th Annual Immuno-Oncology 360 Conference (IO360)
For more information about IO360, please visit https://io360summit.com .
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Investors: lstern@meruadvisors.com
Media: achillestx@consilium-comms.com
What is the ticker symbol for Achilles Therapeutics plc?
The ticker symbol for Achilles Therapeutics plc is ACHL.
What is the focus of the presentation at the 10th Annual Immuno-Oncology 360 Conference?
The presentation will focus on targeting clonal neoantigens with precision cell therapies for solid tumors.
Who will be leading the presentation at the conference?
Sergio Quezada, PhD, the Chief Scientific Officer, will be leading the presentation.
When and where will the presentation take place?
The presentation will take place at the New York Marriott at The Brooklyn Bridge in Brooklyn, NY, on February 29, 2024, at 10:30am ET.
Achilles Therapeutics Plc
ACHL Rankings
#4769 Ranked by Stock Gains
ACHL Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Country
United Kingdom
City
245 Hammersmith Road
About ACHL
achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.
